Clinical Trials

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Other solid neoplasmThoracic

7 enrolled

Mesothelioma, Malignant

NCT06635824 2026-03-12

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Phase 4 Active not recruiting

Lung Neoplasms

NCT05689671 2026-03-10

ANTELOPE

136 enrolled

Non-Small Cell Lung Cancer Metastatic

NCT04736173 2026-03-09

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02959463 2026-03-06

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Other solid neoplasmThoracic

24 enrolled 11 charts

Mesothelioma, Malignant

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05555732 2026-02-19

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05186974 2026-02-11

EVOKE-02

193 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

DermatologicGenitourinaryThoracic

150 enrolled

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT06698042 2026-02-09

MK-3475A-F84

67 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06311721 2026-01-27

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

315 enrolled

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

351 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

126 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT05614102 2026-01-05

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

DermatologicGenitourinaryThoracic

284 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05609968 2025-12-24

MK-3475-D46

614 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05048797 2025-12-23

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06125197 2025-12-23

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

22 enrolled

Lung Neoplasms

NCT02638090 2025-12-22

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

120 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03634241 2025-12-22

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

45 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06131398 2025-12-22

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

DermatologicGastrointestinalThoracic

77 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06049212 2025-12-19

TroFuse-008

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)